Overview
Petrelintide is an investigational once-weekly amylin analog peptide originally developed by Zealand Pharma and partnered with Roche/Genentech in 2024. Amylin is a natural pancreatic peptide co-secreted with insulin that contributes to satiety, slows gastric emptying, and regulates postprandial glucose. Petrelintide is engineered as a long-acting amylin receptor agonist designed for sustained weekly dosing, with the goal of achieving meaningful weight loss with better gastrointestinal tolerability than GLP-1 receptor agonists. Late-breaking Phase 2 ZUPREME-1 data presented at ADA 2026 in June showed clinically meaningful weight loss with what Roche has described as a 'compelling tolerability profile.' The strategic interest in petrelintide centers on its potential combination with enicepatide (CT-388): pairing an amylin agonist with a dual GLP-1/GIP agonist could deliver additive weight loss while distributing GI side effects across mechanisms. A Phase 2 fixed-dose combination study with enicepatide is targeted to enroll its first patient around mid-2026.
Mechanism of Action
Petrelintide is a long-acting amylin analog that activates amylin receptors (AMY1, AMY2, AMY3 receptor complexes formed by the calcitonin receptor in association with receptor activity-modifying proteins). Activation reduces food intake, slows gastric emptying, and suppresses postprandial glucagon secretion. The molecule is designed for once-weekly subcutaneous dosing.
Potential Benefits
- Once-weekly amylin agonist for weight management
- Tolerability profile distinct from GLP-1-only agonists (less GI burden in early data)
- Combination potential with GLP-1/GIP agonists like enicepatide
Research Dosage Notes
The following reflects doses used in published research studies. This is not medical advice.
Once-weekly subcutaneous; dose regimens under Phase 2 evaluation.
Amino Acid Sequence
Proprietary long-acting amylin analog
Side Effects & Safety
- Mostly mild-to-moderate GI in early data
- Long-term safety still under evaluation
Synergistic Compounds
The following compounds have been studied alongside Petrelintide for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
Enicepatide (CT-388): Roche's biased GLP-1/GIP peptide drops Phase 2 detail at ADA 2026
Roche's enicepatide (CT-388) hit 22.5% placebo-adjusted weight loss at 48 weeks in Phase 2 with no plateau; Phase 3 enrolling.
Canvuparatide one-year data: once-weekly PTH peptide prodrug stays on track for Phase 3
MBX Biosciences reported one-year open-label data for once-weekly canvuparatide in chronic hypoparathyroidism. Phase 3 starts Q3 2026.
State pharmacy boards escalate peptide enforcement: what April–May 2026 actions signal
April–May 2026 actions in TX, FL, CA, and OH show state boards targeting peptide and compounded GLP-1 practices via records, prescriber relationships, and volume.
Peptide Import Inspections Are the New Front Line for Compounding Enforcement (Q1 2026)
New Q1 2026 import data suggests selective border enforcement for unapproved peptides and helps explain why compounding policy is shifting this summer.